All In Biotech

Drug Trial Radar · NCT06206837

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH PF-07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

71

Actual

Start

Feb 19, 2024

Primary completion

Sep 5, 2025

Study completion May 25, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Arvinas Estrogen Receptor, Inc.
First posted
Jan 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). * is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken before starting this study. All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until: * their cancer is no longer responding, or * side effects become too severe. They will have visits at the study clinic about every 4 weeks.

Conditions

  • Breast Cancer

Interventions

  • vepdegestrantDrug

    Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days

  • PF-07220060Drug

    Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-Limiting Toxicities (DLTs): Phase 1bTime frame: Cycle 1 (28 days)
  2. Percentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 2Time frame: From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)

Locations

58 sites in 8 countries. Site status is shown where the registry gives one.

  • Highlands Oncology

    Fayetteville, Arkansas

  • Highlands Oncology

    Rogers, Arkansas

  • Highlands Oncology Group

    Springdale, Arkansas

  • Hoag Health Center Irvine

    Irvine, California

  • Hoag Hospital Irvine

    Irvine, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Clinical and Translational Research Unit (CTRU)

    Palo Alto, California

  • Stanford Cancer Center

    Palo Alto, California

  • Stanford Cancer Institute - Clinical Trials Office

    Palo Alto, California

  • UCSF Medical Center at Mission Bay

    San Francisco, California

  • UCHealth Poudre Valley Hospital

    Fort Collins, Colorado

  • UCHealth Harmony

    Fort Collins, Colorado

  • UCHealth Greeley Hospital

    Greeley, Colorado

  • UCHealth - Medical Center of the Rockies

    Loveland, Colorado

  • Smilow Cancer Hospital - Yale New Haven Health

    New Haven, Connecticut

  • Yale - New Haven Hospital - Yale Cancer Center

    New Haven, Connecticut

  • Smilow Cancer Hospital Phase 1 Unit

    New Haven, Connecticut

  • Smilow Cancer Hospital - Trumbull

    Trumbull, Connecticut

  • START Midwest

    Grand Rapids, Michigan

  • MSK Basking Ridge

    Basking Ridge, New Jersey

  • MSK Monmouth

    Middletown, New Jersey

  • MSK Bergen

    Montvale, New Jersey

  • MSK Commack

    Commack, New York

  • MSK Westchester

    Harrison, New York

  • Rockefeller Outpatient Pavilion (53rd Street)

    New York, New York

  • Evelyn H. Lauder Breast and Imaging Center (BAIC).

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • MSK Nassau

    Uniondale, New York

  • START San Antonio

    San Antonio, Texas

  • University of Utah, Farmington Health Center

    Farmington, Utah

  • University of Utah, Sugar House Health Center

    Salt Lake City, Utah

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • South Jordan Health Center - University of Utah

    South Jordan, Utah

  • START Mountain Region

    West Valley City, Utah

  • Antwerp University Hospital

    Edegem, Antwerpen, Belgium

  • Institut Jules Bordet

    Anderlecht, Bruxelles-capitale, Région de, Belgium

  • UZ Leuven

    Leuven, Vlaams-brabant, Belgium

  • AZ Groeninge Campus Kennedylaan

    Kortrijk, West-vlaanderen, Belgium

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario, Canada

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.